WHO WE ARE

WHO WE ARE

Since its establishment in Suwon, Gyeonggi-do, Korea in 2016, Onegene Biotechnology has been developing the proprietary long-acting multi-ligand presenting platform that overcomes practical limitations in the development of therapeutics with more than three ligands. 
By its effective use, we develop multi-targeting therapeutics for complex diseases such as metabolic, inflammatory diseases, and cancer. We envision that our technology opens a new path in the treatment of complex chronic diseases.

COPYRIGHT INFORMATION GOES ‌ONEGENE BIOTECHNOLOGY © 2016. ALL RIGHTS RESERVED